Bio-Path (NASDAQ:BPTH) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Bio-Path (NASDAQ:BPTH) in a report published on Wednesday. The firm issued a sell rating on the stock.

Separately, Roth Mkm reissued a buy rating and set a $40.00 price objective on shares of Bio-Path in a research report on Thursday, April 18th.

Bio-Path Price Performance

Shares of NASDAQ:BPTH opened at $2.68 on Wednesday. The company’s fifty day moving average price is $4.77 and its 200 day moving average price is $8.35. Bio-Path has a 12 month low of $2.35 and a 12 month high of $44.80. The firm has a market capitalization of $1.82 million, a P/E ratio of -0.07 and a beta of 0.35.

Bio-Path (NASDAQ:BPTH) last announced its quarterly earnings results on Friday, March 8th. The company reported ($5.40) EPS for the quarter, hitting the consensus estimate of ($5.40). During the same quarter last year, the business earned ($10.60) EPS. On average, sell-side analysts anticipate that Bio-Path will post -18.71 EPS for the current year.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.